13.85

1.91% -0.27

After Hours: 13.80 -0.05 -0.36%

Arcturus Therapeutics Holdings Inc (ARCT)

Overview News Price History Option Chain Financials Discussions Forecast Stock Split

Arcturus Therapeutics Holdings Inc stock is traded at $13.85, with a volume of 629.53K. It is down -1.91% in the last 24 hours and down -10.30% over the past month. Arcturus Therapeutics Holdings Inc is an RNA medicines company focused on the development of infectious disease vaccines and opportunities within liver and respiratory rare diseases. It operates in one business segment, which includes all activities related to the discovery, development, and commercialization of messenger RNA medicines. The company's pipeline includes LUNAR-OTC and LUNAR-CF. Its Vaccine candidates include LUNAR-FLU, KOSTAIVE XBB.1.5, KOSTAIVE, and Others.

Previous Close:

$14.12

Open:

$14.34

24h Volume:

629.53K

Relative Volume:

0.69

Market Cap:

$393.66M

Revenue:

$42.35M

Net Income/Loss:

$-78.67M

P/E Ratio:

-4.9181

EPS:

-2.8161

Net Cash Flow:

$-63.18M

1W Performance:

-13.60%

1M Performance:

-10.30%

6M Performance:

+96.18%

1Y Performance:

-31.81%

1-Day Range:

$13.30

$14.48

1-Week Range:

$13.26

$16.55

52-Week Range:

$5.50

$24.17

Arcturus Therapeutics Holdings Inc Stock (ARCT) Company Profile

Name

Arcturus Therapeutics Holdings Inc

Sector

Healthcare (1067)

Industry

Biotechnology (595)

Phone

(858) 900-2660

Address

10285 SCIENCE CENTER DRIVE, SAN DIEGO, CA

Employee

111

Twitter

@ArcturusRx

Next Earnings Date

2026-11-09

Latest SEC Filings

ARCT's Discussions on Twitter

Compare ARCT vs VRTX, REGN, MRNA, ARGX, RVMD

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
ARCT Arcturus Therapeutics Holdings Inc	13.85	393.66M	42.35M	-78.67M	-63.18M	-2.8161
VRTX Vertex Pharmaceuticals Inc	526.19	133.37B	12.34B	4.34B	3.71B	16.87
REGN Regeneron Pharmaceuticals Inc	788.04	81.13B	14.92B	4.42B	3.79B	41.04
MRNA Moderna Inc	198.88	79.40B	2.23B	-3.19B	-1.60B	-8.1462
ARGX Argen X Se Adr	959.49	60.03B	4.16B	1.29B	734.26M	19.58
RVMD Revolution Medicines Inc	204.97	43.93B	742.00K	-1.37B	-1.07B	-7.0731

Arcturus Therapeutics Holdings Inc Stock (ARCT) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Mar-18-26	Initiated	B. Riley Securities	Buy
Jan-23-26	Initiated	Roth Capital	Buy
Oct-24-25	Downgrade	H.C. Wainwright	Buy → Neutral
Oct-23-25	Downgrade	Citigroup	Buy → Neutral
Oct-22-25	Downgrade	Guggenheim	Buy → Neutral
Sep-04-25	Resumed	H.C. Wainwright	Buy
May-28-25	Initiated	Scotiabank	Sector Outperform
Jan-28-25	Initiated	BTIG Research	Buy
Aug-12-24	Initiated	Leerink Partners	Outperform
Dec-13-23	Initiated	Canaccord Genuity	Buy
Jul-24-23	Initiated	William Blair	Outperform
May-11-23	Upgrade	H.C. Wainwright	Neutral → Buy
Nov-14-22	Resumed	Wells Fargo	Overweight
Nov-10-22	Downgrade	Robert W. Baird	Neutral → Underperform
Nov-03-22	Upgrade	Citigroup	Neutral → Buy
Nov-02-22	Upgrade	Barclays	Underweight → Equal Weight
Aug-10-22	Downgrade	Raymond James	Mkt Perform → Underperform
Jul-19-22	Resumed	Cantor Fitzgerald	Overweight
May-11-22	Upgrade	Robert W. Baird	Underperform → Neutral
Apr-21-22	Downgrade	Citigroup	Buy → Neutral
Jan-31-22	Upgrade	Raymond James	Underperform → Mkt Perform
Aug-12-21	Downgrade	Raymond James	Mkt Perform → Underperform
Aug-11-21	Downgrade	Goldman	Neutral → Sell
Aug-10-21	Downgrade	Robert W. Baird	Neutral → Underperform
Jul-02-21	Initiated	Cantor Fitzgerald	Overweight
Jun-25-21	Resumed	Goldman	Neutral
Jun-21-21	Downgrade	Barclays	Equal Weight → Underweight
Jun-04-21	Resumed	Robert W. Baird	Neutral
Feb-17-21	Downgrade	B. Riley Securities	Neutral → Sell
Jan-19-21	Downgrade	B. Riley Securities	Buy → Neutral
Jan-15-21	Downgrade	B. Riley Securities	Buy → Neutral
Jan-07-21	Initiated	Wells Fargo	Overweight
Dec-29-20	Downgrade	Barclays	Overweight → Equal Weight
Dec-29-20	Downgrade	H.C. Wainwright	Buy → Neutral
Dec-29-20	Downgrade	Raymond James	Outperform → Mkt Perform
Dec-29-20	Downgrade	Robert W. Baird	Outperform → Neutral
Dec-23-20	Downgrade	ROTH Capital	Buy → Sell
Dec-08-20	Reiterated	B. Riley Securities	Buy
Dec-07-20	Reiterated	B. Riley Securities	Buy
Oct-26-20	Initiated	Barclays	Overweight
Oct-06-20	Initiated	Citigroup	Buy
Aug-26-20	Initiated	Piper Sandler	Overweight
Jul-30-20	Resumed	ROTH Capital	Buy
Jul-16-20	Initiated	Raymond James	Outperform
Jul-13-20	Initiated	B. Riley FBR	Buy
Jun-09-20	Downgrade	WBB Securities	Buy → Hold
Feb-11-20	Initiated	Robert W. Baird	Outperform
Feb-07-20	Initiated	Guggenheim	Buy
Feb-06-20	Initiated	Guggenheim	Buy
Apr-05-19	Initiated	H.C. Wainwright	Buy
Sep-20-18	Upgrade	WBB Securities	Buy → Strong Buy
Jan-22-18	Initiated	Chardan Capital Markets	Buy

View All

Arcturus Therapeutics Holdings Inc Stock (ARCT) Latest News

Sep 26, 2026

(ARCT) Movement Within Algorithmic Entry Frameworks - Stock Traders Daily

Sep 26, 2026

Sep 25, 2026

A Quick Look at Today's Ratings for Arcturus Therapeutics(ARCT.US), With a Forecast Between $20 to $41 - Moomoo

Sep 25, 2026

Sep 24, 2026

Arcturus Highlights ARCT-810 Phase II Data, Unveils Next-Gen OTC Therapy Platform - Yahoo Finance

Sep 24, 2026

Arcturus Therapeutics Shares Rise After OTC Deficiency Data, Citigroup Upgrade - marketscreener.com

Sep 24, 2026

Why Is Arcturus Therapeutics Stock Gaining Thursday? - benzinga.com

Sep 24, 2026

Arcturus Gets Citi Upgrade After Positive Liver Disease Study Data – But BTIG Says Therapy’s Benefit Is Hard To Measure - Yahoo Finance

Sep 24, 2026

Everpure, Fervo Energy, Charles River Laboratories And Other Big Stocks Moving Higher On Thursday - benzinga.com

Sep 24, 2026

Citigroup Upgrades Arcturus Therapeutics to Buy From Neutral, Adjusts PT to $20 From $8 - marketscreener.com

Sep 24, 2026

ARCT Maintained by BTIG -- Price Target Lowered to $20 - GuruFocus

Sep 24, 2026

Citi Upgrades Arcturus Therapeutics(ARCT.US) to Buy Rating, Raises Target Price to $20 - Moomoo

Sep 24, 2026